Methods for reducing the risk of hypoglycemia
AssigneeDiObex, Inc.
InventorsDaniel T. Green, Robert R. Henry
Life of this patent
Estimating the term…
Abstract
Pharmaceutical compositions comprising glucagon can be administered to control and treat diabetes while reducing or eliminating the risk of insulin-induced hypoglycemia. Also provided are methods of administering glucagon so as to reduce the risk of hypoglycemia.
Claims20
A method for reducing a risk of an onset of hypoglycemia in a subject who is not experiencing hypoglycemia, said method comprising administering glucagon to said subject in an amount equivalent to a subcutaneous administration of glucagon at a rate of 2 to 16 ng of glucagon per kg of subject weight per minute.
A method of reducing a risk of an onset of hypoglycemia in a non-hypoglycemic subject without inducing hyperglycemia, said method comprising administering glucagon in a dose equivalent to a subcutaneous administration of 2 to 16 ng of glucagon per kg of subject weight per minute of desired effectiveness.
A method of reducing a risk of hypoglycemia without inducing hyperglycemia, which method comprises:
- administering glucagon subcutaneously;
- wherein administration of glucagon occurs daily;
- wherein when said glucagon is administered the subject has a blood glucose level of at least 70 mg/dL and is not exhibiting hypoglycemic symptoms
- wherein said glucagon is administered subcutaneously in a dosage that provides 2 to 16 ng of glucagon per kilogram of subject weight per minute;
- and
- wherein said subcutaneous administration provides plasma glucagon levels that are sustained for 6 to 8 hours in the range of 100 to 200 pg/ml.
Dependencies are inferred from the claim text.